STI571 (Gleevec™) as a paradigm for cancer therapy

Trends in Molecular Medicine

Volumn 8, Issue 4 SUPPL., 2002, Pages

  Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; HUMAN; PATIENT SELECTION; REVIEW; TREATMENT INDICATION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0036216405     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02305-5     Document Type: Review

References (37)

1. Chronic myelogenous leukemia: Biology and therapy
2. Chronic myeloid leukemia
3. Chronic myeloid leukemia: Current treatment options
4. A minute chromosome in human chronic granulocytic leukemia
5. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining
6. The molecular biology of chronic myeloid leukemia
7. Lymphosarcoma: Virus-induced thymic-independent disease in mice
8. A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity
9. The molecular biology of chronic myeloid leukemia
10. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
11. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
12. Acute leukaemia in bcr/abl transgenic mice
13. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
14. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells
15. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
16. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ ABL+ leukemic cells and induces apoptosis
17. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
18. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
19. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
20. Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome positive chronic myeloid leukemia
21. A Phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
22. A Phase II study of STIS71 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
23. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
24. Roots of clinical resistance to STI-571 cancer therapy
25. Roots of clinical resistance to STI-571 cancer therapy
26. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
27. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
28. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-KIT (CD117)
29. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC Phase I study
30. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
31. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571
32. STI571 inhibits the kinase activity of wild type and juxtamembrane c-kit mutants but not the exon 17 D816V mutation associated with mastocytosis
33. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5; 12) chromosomal translocation
34. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins
35. Chronic myeloproliferative diseases with t(5; 12) and a PDGFRB fusion gene: Complete cytogenetic remissions on STI571
36. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
37. Protein tyrosine kinases and cancer